Vanguard Asset Management
TBPH icon

Vanguard Asset Management’s Theravance Biopharma TBPH Stock Holding History

Vanguard Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Hold
25,612
– – ﹤0.01% 2238
2026
Q1 		$416K Buy
+25,612
New +$453K ﹤0.01% 2180

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's TBPH Position: Q2 2026 in Review

Vanguard Asset Management held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 25,612 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Vanguard Asset Management first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Vanguard Asset Management held 25,612 shares of Theravance Biopharma worth $435K as of Q2 2026.
  • Vanguard Asset Management left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2238 holding.
  • Vanguard Asset Management first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 166 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.